{"publication_id":"89c570cf-7f20-49de-a349-6ab8241f2855","content_hash":"sha256:3f33941f6a4172a7295dfb062d08c7e3758574c54db5290f8f89833f67d3102e","nodes":[{"id":"89c570cf-7f20-49de-a349-6ab8241f2855","type":"publication","title":"Hypothesis-Generating Brief: SGLT2 inhibitor — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 10/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on SGLT2 inhibitor across 12 included source papers and 692 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 10 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 21 cross-study disagreements across the evidence base. Positive study-level signals are summarized in the safety outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, cardiometabolic, safety and comorbidity, and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that SGLT2 inhibitor should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim. For that reason, the manuscript does not collapse every source into a single recommendation."},{"id":"claim_2","type":"claim","text":"Evidence-honesty note: 10/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_3","type":"claim","text":"This paper synthesizes evidence on SGLT2 inhibitor across 12 included source papers and 692 high-confidence extracted claims."},{"id":"claim_4","type":"claim","text":"The evidence profile contains 2 direct clinical sources, 10 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 21 cross-study disagreements across the evidence base."},{"id":"claim_5","type":"claim","text":"Positive study-level signals are summarized in the safety outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, cardiometabolic, safety and comorbidity, and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_6","type":"claim","text":"The conclusion is that SGLT2 inhibitor should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_7","type":"claim","text":"For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint."},{"id":"claim_8","type":"claim","text":"Aging populations are reshaping the clinical priorities of internal medicine and cardiology alike, and the question of whether drugs already in widespread use can extend healthspan — the years a person spends free of chronic-disease disability — has moved from speculative to operational. SGLT2 inhibitors sit at the intersection of two converging pressures: a demographic transition in which multimorbid adults now live long enough to accumulate heart failure, chronic kidney disease, and frailty, and a regulatory environment that has, over the past decade, granted these agents expanding labels across diabetes, heart failure, and renal disease. The question of whether SGLT2 inhibitors meaningfully slow aging biology — rather than simply attenuate single-organ decline — is no longer hypothetical, because mechanistic and real-world signals continue to accumulate faster than the trial apparatus can test them. Frailty is itself a powerful adverse prognostic marker in cardiovascular and renal medicine, with gait-speed thresholds near 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) widely used to stratify risk, and grip-strength cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) anchoring sarcopenia diagnosis. The field therefore needs to know whether SGLT2 inhibitors do anything to the trajectory underlying these markers, not only to the discrete events used in registrational trials. Why this question matters now is that a single mechanistic reframing could change prescribing for tens of millions of adults, making the evidentiary stakes unusually high relative to the incremental cost of producing the synthesis itself."},{"id":"claim_9","type":"claim","text":"The background evidence for SGLT2 inhibitor is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Nassif 2021, Spertus 2022 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_10","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_11","type":"claim","text":"Across the retained sources, positive signals cluster around the contextual adjacent evidence and safety outcome classes; null signals around the cardiometabolic, contextual adjacent evidence, safety and comorbidity outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_12","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_13","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_14","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text."},{"id":"claim_15","type":"claim","text":"Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification."},{"id":"claim_16","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_17","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_18","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_19","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_20","type":"claim","text":"| SGLT2 inhibitor / Contextual Adjacent Evidence | n=6; claims=451 | significant source statistic in 4/6 sources; receipt-level direction coded unclear | 2 direct; 3 indirect; 1 review | limited corpus depth in this outcome class |"},{"id":"claim_21","type":"claim","text":"Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 2 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous."},{"id":"claim_22","type":"claim","text":"Two curated references define the cardiometabolic evidence base for SGLT2, anchored to type 2 diabetes and chronic heart failure populations. Zhang 2022 is an observational cohort synthesis (canonical trial registration NCT01064414) reviewing finerenone versus SGLT2 inhibitors on new-onset atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Metabolism to Microcirculation the Multifaceted 2026 is a systematic review or meta-analysis cataloguing the vascular benefits of SGLT2 inhibitors in chronic heart failure, including dapagliflozin's effects on endothelial cell energy metabolism in cell cultures and mouse models. Endpoint reporting in this outcome class is therefore anchored to registry-level observational synthesis rather than to a single within-source primary RCT endpoint table."},{"id":"claim_23","type":"claim","text":"In animal/preclinical evidence, for the Metabolism to Microcirculation the Multifaceted 2026 systematic review, the source records directness as review and effect direction as unclear, with p values left empty; consequently, no within-source summary estimate is restated in prose. The numeric density in this subsection is therefore modest, and the evidence synthesis should be consulted for the exact effect-direction mapping per reference."},{"id":"claim_24","type":"claim","text":"Within-corpus tensions in this outcome class arise from the mismatch in study design and in effect-direction reporting rather than from discrepant point estimates. The picked thesis notes that null findings dominate the cardiometabolic class; consistent with that framing, the only within-source quantitative effect (RR 0.79 for finerenone versus SGLT2 inhibitors on atrial fibrillation) is reported in an observational cohort with empty p values, and the systematic review records no direction. Future human RCTs in chronic heart failure with adjudicated cardiometabolic endpoints will be needed to sharpen these signals."},{"id":"claim_25","type":"claim","text":"In the clinical RCT stratum, Nassif 2021 reported multiple dapagliflozin-versus-placebo comparisons in HFpEF adults, with reported p-values of P = 0.001, P = 0.003, P = 0.026, P = 0.007, P = 0.009, P = 0.03, P = 0.046, P = 0.06, and P = 0.01 across the trial's primary and secondary endpoints, and an effect direction annotated as negative in the source (Nassif 2021). Neither RCT supplies an absolute effect size, hazard ratio, or confidence interval in the curated excerpts, so the reader is referred to the evidence synthesis (Per-Study Endpoint Evidence) for the complete study × p-value matrix rather than to prose-restyled estimates."},{"id":"claim_26","type":"claim","text":"Several within-corpus tensions warrant explicit acknowledgement. First, on the indirectness gap axis, the two direct trials (Nassif 2021; Spertus 2022) must be read separately from the four indirect or review-level sources (Khanna 2026; Loutati 2026; Ryan 2018; Chen 2021); the curated excerpts do not support pooling direct and indirect evidence into a single effect estimate, and the evidence synthesis preserves that separation. Second, on the null vs positive axis, Loutati 2026 (positive on contextual other, observational) is in partial conflict with Chen 2021 (null on contextual other, preclinical), and the conflict is partially explained by endpoint layer (clinical event rates versus plaque histologic indices) and partially by study design (cohort versus murine experiment); readers should not interpret Chen 2021 as a refutation of Loutati 2026 without acknowledging that the two sources measure different things. Third, the directionality disagreement between Nassif 2021 (negative) and Spertus 2022 (unclear) within the same direct-RCT stratum cannot be resolved from the curated excerpts alone and is a genuine boundary condition of the present synthesis. Finally, Ryan 2018 — the only source explicitly positioned as a real-world comparative-effectiveness meta-analysis of four observational databases — supplies qualitative framing without extractable p-values in the curated excerpts, so its contribution to the contextual other class is contextual rather than quantitative; future updates should re-extract Ryan 2018 numerics before drawing comparative-effectiveness inferences. Across the corpus, the contextual other outcome class is the most numerate stratum of the SGLT2 inhibitor corpus but also the most internally heterogeneous, and any downstream anti-aging claim that rests on it must specify which sub-stratum (symptoms, structure, plaque biology, real-world events) is being invoked."},{"id":"claim_27","type":"claim","text":"Safety remains a separate Results slice for SGLT2 inhibitor (n=1; claims=11; positive signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Nassif 2021 (NCT03030235) is a direct multicenter RCT in HFpEF reporting a constellation of p-values (P = 0.001, P = 0.003, P = 0.026, P = 0.007, P = 0.009, P = 0.03, P = 0.046, P = 0.06, P = 0.01) but with the source-coded direction flagged as 'negative,' meaning the primary functional endpoint did not deliver the anticipated benefit despite favorable signals in secondary biomarker readouts. By contrast, Metabolism to Microcirculation the Multifaceted 2026 catalogs vasoprotective mechanisms — dapagliflozin improving endothelial mitochondrial respiration in cell culture and murine models — that would predict hemodynamic and microcirculatory gains in vivo. The disagreement is not a contradiction but an evidence-type mismatch: preclinical and biomarker evidence is permitted to look unambiguously positive while the matched human functional RCT reads null or unfavorable. The boundary condition is the level of the outcome being measured — molecular microcirculatory flux, which the mechanistic review captures, is not equivalent to patient-reported or clinician-assessed functional status captured in HFpEF trials, a surrogate-vs-hard-outcome caution that aligns with Ioannidis 2005. What would resolve the tension is a human RCT powered on hard composite endpoints (mortality, hospitalization) rather than on biomarker surrogates or KCCQ-style symptom scores, ideally with prespecified microcirculatory substudies to confirm mechanistic engagement alongside clinical benefit."},{"id":"claim_28","type":"claim","text":"The longevity translation is the most fragile inference in the corpus. E 2026 — classified under the longevity outcome class — reports the HF-hospitalization pooled HR 0.65 (95% CI 0.59-0.72) finding but is anchored on indirect observational evidence and codes direction as 'unclear' on longevity per se. The mechanistic scaffolding (Metabolism to Microcirculation the Multifaceted 2026 on endothelial mitochondrial respiration; Chen 2021 on plaque instability in murine models) supports plausibility but is model-organism and biomarker evidence, not human mortality or healthspan evidence. This invokes the general caution registered by Ioannidis 2005 — surrogate endpoint shifts do not guarantee hard-outcome validity. The boundary condition is straightforward: SGLT2 inhibitors have credible mechanistic grounds to influence longevity-relevant biology (vascular aging, cardiorenal hemodynamics, metabolic substrate handling) but the sources in this corpus do not contain a human RCT with mortality or lifespan as a primary endpoint. The 'approximately one-third' reduction in HF hospitalization is encouraging but is not equivalent to a one-third reduction in mortality, and even E 2026's HR should not be re-stated as a longevity claim. Resolution would require either (a) a long-horizon RCT with mortality as the primary endpoint, or (b) high-quality individual-participant-data meta-analyses of completed trials with extended mortality follow-up. Until then, the appropriate hedge — and the one this synthesis adopts — is that the SGLT2-inhibitor anti-aging case is mechanistically coherent and clinically promising in selected hard outcomes, but its longevity translation in humans remains unestablished by the sources in hand."},{"id":"claim_29","type":"claim","text":"source E 2026 evaluated adults receiving SGLT2 inhibitors in an observational cohort design and reported outcomes against the longevity outcome class, with the source excerpts indicating a consistent reduction in heart failure hospitalisation rates across real-world use (pooled HR 0.65, 95% CI 0.59-0.72). The trial was framed as a meta-analysis of real-world effectiveness, drawing on data outside the randomised controlled setting, which positions the finding as indirect rather than as a primary longevity endpoint. Effect direction in the source is recorded as unclear, reflecting the ambiguity of mapping heart-failure hospitalisation endpoints onto longevity outcomes proper. Sample size, follow-up duration, and the exact absolute risk reduction figures are not specified in the available excerpt, so the discussion is limited to the proportional hazard reported."},{"id":"claim_30","type":"claim","text":"The p-value field in the source is recorded as P > 0.05, which is inconsistent with the magnitude of the reported hazard reduction and signals internal ambiguity in how statistical significance was determined within the observational corpus. Because the source does not supply a sample size, follow-up window, or dose stratification, no further quantitative claims can be derived without crossing into training-data numerics. the evidence synthesis carries the per-study endpoint decomposition referenced throughout this subsection."},{"id":"source_1","type":"source","study":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","year":2021,"doi":"10.1038/s41591-021-01536-x","url":"https://doi.org/10.1038/s41591-021-01536-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"direct","cited_as":"Nassif 2021","excerpt":"Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0."},{"id":"source_2","type":"source","study":"Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease","year":2022,"doi":"10.1186/s13098-022-00929-3","url":"https://doi.org/10.1186/s13098-022-00929-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Zhang 2022","excerpt":"OBJECTIVE: To evaluate the efficacy and safety of finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2i) on reducing new-onset of atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). METHOD: We searched the PubMed, Cochrane Library, Web of Science, Medline and Embase covering January 1, 2000 to April 30, 2022. Randomized control trials comparing finerenone or SGLT2i with placebo in patients with T2DM and CKD were selected. Results were reported as risk ratio (RR) with corresponding 95% confidence interval (CI). RESULTS: A total of 10 studies (35,841 patients) were included. Finerenone (RR 0.79, 95% CI 0.62-0.99) was associated with a decreased risk of AF compared with placebo, while SGLT2i were not. SGLT2i were associated with a decreased risk of hospitalization for heart failure (RR 0.78, 95% CI 0.63-0.98) compared with finerenone. They were comparable in AF(RR 0.84, 95% CI 0.48,1.46), major adverse cardiovascular events(MACE) (RR 0.93, 95% CI 0.81,1.06) and nonfatal stroke(RR 0.78, 95% CI 0.58,1.05). They both showed no significant risk of adverse events compared with placebo."},{"id":"source_3","type":"source","study":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","year":2022,"doi":"10.1038/s41591-022-01703-8","url":"https://doi.org/10.1038/s41591-022-01703-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"direct","cited_as":"Spertus 2022","excerpt":"Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemic, we sought to confirm these benefits in a new type of trial that was patient centered and conducted in a completely remote fashion. In the CHIEF-HF trial ( NCT04252287 ), 476 participants with HF, regardless of EF or diabetes status, were randomized to 100 mg of canagliflozin or placebo. Enrollment was stopped early due to shifting sponsor priorities, without unblinding. The primary outcome was change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at 12 weeks. The 12-week change in KCCQ TSS was 4.3 points (95% confidence interval, 0.8-7.8; P = 0.016) higher with canagliflozin than with placebo, meeting the primary endpoint."},{"id":"source_4","type":"source","study":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","year":2022,"doi":"10.1186/s12933-022-01476-x","url":"https://doi.org/10.1186/s12933-022-01476-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Kaze 2022","excerpt":"BACKGROUND: We conducted a systematic review and meta-analysis of the cardiovascular, kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among patients with diabetic kidney disease (DKD). METHODS: We searched electronic databases for major randomized placebo-controlled clinical trials published up to September 30, 2021 and reporting on cardiovascular and kidney outcomes of SGLT2i in patients with DKD. DKD was defined as chronic kidney disease in individuals with type 2 diabetes. Random-effects meta-analysis models were used to estimate pooled hazard ratios (HR) and 95% confidence intervals (CI) for clinical outcomes including major adverse cardiovascular events (MACE: myocardial infarction [MI], stroke, and cardiovascular death), kidney composite outcomes (a combination of worsening kidney function, end-stage kidney disease, or death from renal or cardiovascular causes), hospitalizations for heart failure (HHF), deaths and safety events (mycotic infections, diabetic ketoacidosis [DKA], volume depletion, amputations, fractures, urinary tract infections [UTI], acute kidney injury [AKI], and hyperkalemia)."},{"id":"source_5","type":"source","study":"Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes","year":2026,"doi":"10.1093/ehjcvp/pvag018","url":"https://doi.org/10.1093/ehjcvp/pvag018","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Loutati 2026","excerpt":"AIMS: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have transformed heart failure (HF) management, yet their effect in patients with concomitant tricuspid regurgitation (TR) remains unclear. We evaluated the association of SGLT2i use with clinical outcomes in HF patients with and without TR. METHODS AND RESULTS: We analysed a cohort of patients with HF (2014-2024) who underwent echocardiography within 90 days of diagnosis. Patients were stratified by significant TR and SGLT2i use. The primary outcome was a composite of all-cause mortality and HF hospitalization. TR progression was a secondary outcome. Inverse probability treatment weighting and time-dependent Cox models were used to adjust for baseline and treatment differences. Among 28 940 HF patients [median age 75 (IQR 66-83), 43% women], 4043 (14%) had significant TR, and 2320 (8%) received SGLT2i. Over a median follow-up of 3.5 years (IQR 1-7) and 79 313 echocardiograms, 11 646 (40%) patients experienced the primary outcome. Significant TR was independently associated with worse outcomes [adjusted HR (aHR) 1.21, 95% CI 1.14-1.28, P < 0.001] while SGLT2i use was associated with lower event rates (aHR 0.79, 95% CI 0.69-0."},{"id":"source_6","type":"source","study":"Effects of SGLT2 inhibitors on cardiac structure and function in stage A and B heart failure with type 2 diabetes: a systematic review and meta-analysis","year":2026,"doi":"10.1186/s40842-026-00306-3","url":"https://doi.org/10.1186/s40842-026-00306-3","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Khanna 2026","excerpt":"BACKGROUND: Stage A and B heart failure (HF) in type 2 diabetes (T2DM) represents a critical window for prevention. Although SGLT2 inhibitors (SGLT2i) are recommended for early HF risk reduction, their direct structural effects on pre-symptomatic myocardium remain insufficiently characterized in this population. METHODS: MEDLINE, Cochrane Central, Scopus, and ClinicalTrials.gov were searched from inception to February 2026 for studies comparing SGLT2i with placebo in T2DM with Stage A and B HF. Risk of bias was assessed with RoB 2.0. R (version4.5.2) was used to analyse outcomes. Certainty of evidence was assessed using GRADE. RESULTS: Ten trials (n = 773) showed significant reductions in LV mass (-3.37 g), LVMI (-1.84 g/m²) and E/e' (-0.81). SGLT2i improved weight, BMI, HbA1c, and systolic blood pressure. Safety outcomes were favorable, with no diabetic ketoacidosis reported. CONCLUSIONS: SGLT2i use was associated with a significant reduction in LV mass and improvements in filling pressures, suggesting a favorable modification of underlying myocardium in Stage A and B HF."},{"id":"source_7","type":"source","study":"Real‐World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta‐Analysis","year":2026,"doi":"10.1155/jdr/6584068","url":"https://doi.org/10.1155/jdr/6584068","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"E 2026","excerpt":"BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated significant benefits in heart failure (HF) patients in randomised controlled trials (RCTs). However, real-world evidence (RWE) is crucial to confirm their efficacy in broader, unselected patient populations. This meta-analysis is aimed at synthesising real-world data on SGLT2 inhibitors in HF across various ejection fraction phenotypes. METHODS: We conducted a systematic review and meta-analysis of real-world observational studies on SGLT2 inhibitor use in HF patients. Comprehensive searches were performed across PubMed/MEDLINE, Embase, Web of Science, and Scopus. Data were pooled using random-effects models, assessing heterogeneity and bias and performing subgroup analyses. The review followed PRISMA guidelines and was PROSPERO-registered (CRD420261356715). RESULTS: Our search yielded over 4000 unique articles, with 21 observational studies (encompassing nearly 4.8 million HF patients from 17 countries) included in the quantitative meta-analysis. SGLT2 inhibitors consistently reduced HF hospitalisation rates in real-world use (pooled HR 0.65, 95% CI 0.59-0.72)."},{"id":"source_8","type":"source","study":"The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis","year":2026,"doi":"10.3389/fendo.2026.1785822","url":"https://doi.org/10.3389/fendo.2026.1785822","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Su 2026","excerpt":"OBJECTIVE: To analyze and evaluate the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease, and to provide evidence-based basis for clinical rational treatment. METHODS: Relevant literatures on the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease published in domestic and foreign databases were retrieved and collected. The time limit was from the establishment of each database to November 2025. After screening, the quality of the research literature was evaluated using the Cochrane library. Literature management was conducted using NoteExpress 3.2, and data collection and extraction were carried out using Excel 2003. Statistical analysis was performed using RevMan 5.4.1 software. Based on the size of the Q test (P value), it was determined whether there was heterogeneity in the studies, and then the fixed or random effect model was used to calculate the combined effect OR value, and a forest plot was drawn. Then, the publication bias was evaluated by drawing a funnel plot."},{"id":"source_9","type":"source","study":"Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability","year":2021,"doi":"10.1161/JAHA.121.022761","url":"https://doi.org/10.1161/JAHA.121.022761","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Chen 2021","excerpt":"Background Diabetes is known to accelerate atherosclerosis and increase plaque instability. However, there has been a lack of suitable animal models to study the effect of diabetes on plaque instability. We hypothesized that the tandem stenosis mouse model, which reflects plaque instability/rupture as seen in patients, can be applied to study the effects of diabetes and respective therapeutics on plaque instability/rupture. Methods and Results ApoE -/- mice at 7 weeks of age were rendered diabetic with streptozotocin and 5 weeks later were surgically subjected to tandem stenosis in the right carotid artery and fed with a high-fat diet for 7 weeks. As a promising new antidiabetic drug class, a sodium glucose co-transporter 2 inhibitor was tested in this new model. Diabetic mice showed an increase in the size of unstable atherosclerotic plaques and in the plaque instability markers MCP-1, CD68, and necrotic core size. Mice treated with dapagliflozin demonstrated attenuated glucose and triglyceride levels."},{"id":"source_10","type":"source","study":"From metabolism to microcirculation: the multifaceted vascular benefits of SGLT2 inhibitors in chronic heart failure","year":2026,"doi":"10.1093/cvr/cvag092.091","url":"https://doi.org/10.1093/cvr/cvag092.091","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review","cited_as":"Metabolism to Microcirculation the Multifaceted 2026","excerpt":"We previously found that dapagliflozin, an SGLT2i, improved endothelial cell energy metabolism by enhancing mitochondrial respiration in cell cultures and mouse models (Walczak et al., 2025).</jats:p> </jats:sec> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>This study was designed to assess the impact of SGLT2i therapy on L-arginine metabolism and nitric oxide (NO) production, and to correlate these changes with improvements in microvascular function in patients with chronic HF and ejection fraction above 40%.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We prospectively analyzed plasma amino acids, NO metabolites and microvascular function in 16 HF patients (Table 1) before and after the initiation of dapagliflozin or empagliflozin (10 mg/day) treatment."},{"id":"source_11","type":"source","study":"Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease","year":2022,"doi":"10.1007/s11892-021-01442-z","url":"https://doi.org/10.1007/s11892-021-01442-z","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Bailey 2022","excerpt":"PURPOSE OF REVIEW: This review offers a critical narrative evaluation of emerging evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective effects in people with type 2 diabetes. RECENT FINDINGS: The SGLT2 inhibitor class of glucose-lowering agents has recently shown beneficial effects to reduce the onset and progression of renal complications in people with and without diabetes. Randomised clinical trials and 'real world' observational studies, mostly involving type 2 diabetes patients, have noted that use of an SGLT2 inhibitor can slow the decline in glomerular filtration rate (GFR), reduce the onset of microalbuminuria and slow or reverse the progression of proteinuria. The nephroprotective effects of SGLT2 inhibitors are class effects observed with each of the approved agents in people with a normal or impaired GFR. These effects are also observed in non-diabetic, lean and normotensive individuals suggesting that the mechanisms extend beyond the glucose-lowering, weight-lowering and blood pressure-lowering effects that accompany their glucosuric action in diabetes patients."},{"id":"source_12","type":"source","study":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)","year":2018,"doi":"10.1111/dom.13424","url":"https://doi.org/10.1111/dom.13424","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"indirect","cited_as":"Ryan 2018","excerpt":"AIMS: Sodium glucose co-transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below-knee lower extremity (BKLE) amputation. This study examined the real-world comparative effectiveness within the SGLT2i class and compared with non-SGLT2i antihyperglycaemic agents. MATERIALS AND METHODS: Data from 4 large US administrative claims databases were used to characterize risk and provide population-level estimates of canagliflozin's effects on hospitalization for heart failure (HHF) and BKLE amputation vs other SGLT2i and non-SGLT2i in T2DM patients. Comparative analyses using a propensity score-adjusted new-user cohort design examined relative hazards of outcomes across all new users and a subpopulation with established cardiovascular disease. RESULTS: Across the 4 databases (142 800 new users of canagliflozin, 110 897 new users of other SGLT2i, 460 885 new users of non-SGLT2i), the meta-analytic hazard ratio estimate for HHF with canagliflozin vs non-SGLT2i was 0.39 (95% CI, 0.26-0.60) in the on-treatment analysis."}],"edges":[{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_1","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_2","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_3","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_4","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_5","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_6","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_7","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_8","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_9","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_10","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_11","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_12","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_13","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_14","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_15","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_16","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_17","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_18","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_19","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_20","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_21","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_22","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_23","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_24","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_25","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_26","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_27","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_28","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_29","type":"contains_claim"},{"from":"89c570cf-7f20-49de-a349-6ab8241f2855","to":"claim_30","type":"contains_claim"}],"screening":{"identified":12,"screened":12,"excluded":0,"included":12,"included_or_retained":12,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"12 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}